Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total transaction of $87,455.08. Following the completion of the transaction, the director now directly owns 7,066,113 shares of the company’s stock, valued at $53,985,103.32. This trade represents a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, October 29th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.72, for a total transaction of $76,923.84.
• On Tuesday, October 15th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.67, for a total transaction of $76,351.49.
• On Tuesday, October 1st, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.22, for a total transaction of $71,200.34.
• On Tuesday, September 17th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.84, for a total transaction of $78,297.48.
• On Tuesday, September 3rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.27, for a total transaction of $71,772.69.
• On Tuesday, August 20th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.12, for a total transaction of $81,502.64.

Recursion Pharmaceuticals Price Performance

Shares of RXRX traded down $0.41 during mid-day trading on Thursday, reaching $6.91. The stock had a trading volume of 6,567,201 shares, compared to its average volume of 5,730,846. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -4.78 and a beta of 0.81. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.89 and a 12 month high of $15.74. The business has a fifty day moving average of $6.64 and a 200 day moving average of $7.62. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.43) earnings per share. Equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Arete Wealth Advisors LLC bought a new position in shares of Recursion Pharmaceuticals during the third quarter worth $77,000. Rockefeller Capital Management L.P. bought a new position in shares of Recursion Pharmaceuticals during the third quarter worth $439,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Recursion Pharmaceuticals by 2.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,140,750 shares of the company’s stock worth $14,108,000 after acquiring an additional 43,078 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Recursion Pharmaceuticals by 5.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company’s stock worth $346,000 after acquiring an additional 2,667 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its position in shares of Recursion Pharmaceuticals by 13.7% during the third quarter. MetLife Investment Management LLC now owns 136,541 shares of the company’s stock worth $900,000 after acquiring an additional 16,405 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

RXRX has been the subject of several recent research reports. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, November 7th. Jefferies Financial Group cut their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Finally, Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.